Per-capita consumption of analgesics: a nine-country survey over 20 years by H.-C. Diener et al.
ORIGINAL ARTICLE
Per-capita consumption of analgesics: a nine-country survey
over 20 years
H.-C. Diener Æ R. Schneider Æ B. Aicher
Received: 14 March 2008 / Accepted: 21 May 2008 / Published online: 10 July 2008
 Springer-Verlag 2008
Abstract There are no reliable data at present on use of
analgesics in various countries. We compared per-capita
consumption in nine different countries during the period
1986–2005. The per-capita consumption was calculated on
the basis of the sales figures of distributors to pharmacies
and direct purchases by pharmaceutical companies in a
sample of 1,000 pharmacies. The countries studied were:
Australia, Austria, Belgium, Canada, France, Germany,
Sweden, Switzerland, and the USA. In international com-
parison Austria, Switzerland, and Germany showed the
lowest per-capita consumption of analgesics (approx. 40–
50 Standard Units (SU) per capita per year), while in
Sweden and France consumption was three times as high.
The correlation analysis over the various countries and
time points confirmed a significant correlation between use
of single analgesics and overall use of analgesics. In Ger-
many, where an allegedly particularly high and constantly
rising analgesic use has been discussed controversially
(Meiner, Pharm Ind 49:1247–1251, 1987), per-capita con-
sumption of analgesics from 1980 to 2005 remained
practically unchanged at approx. 50 SU per capita per year.
The prevalence of conditions inducing analgesic use shows
appropriate analgesics use on an overall population level.
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Introduction
Life-time prevalence of acute pain, in particular headache,
is assumed to be nearly 100%. This means that, i.e. almost
every individual will suffer from some kind of pain (e.g.
headache) during their lifetime. Life-time headache prev-
alence alone is 66% worldwide, in adults in Europe it is
80% for tension-type headache, and 15% for migraine [1].
In most cases analgesics are used for treatment. Pain-
relieving therapy is generally symptom-prompted and
common types of acute pain, such as episodic tension-type
headache or migraine with or without aura, often does not
require intervention by a doctor. This explains why anal-
gesics are among the drugs most frequently used in self-
medication. High safety and good tolerability of a drug are
critical for its OTC authorisation [2]. However, adverse
effects of drugs intended for self-medication cannot be
completely ruled out. Since most adverse drug effects are
dose-related, consumption of drugs—for self-medication in
particular analgesics—is often in the focus of public
interest. Reliable long-term data on the use of analgesics in
different countries are only available for the period from
1970 to 1986 [3]. The purpose of the present examination
was to close the gap over the past 20 years and to provide a
database for further analyses such as epidemiological
studies or studies on the usage pattern of OTC analgesics.
Methods
Data on pharmacies purchases including all sales of the
distributors to pharmacies and, in addition, direct purchases
of pharmacies from pharmaceutical companies were
obtained for a sample of 1,000 pharmacies (statistics by
the Institute of Medical Statistics, IMS, Frankfurt). ‘‘These
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consumption data’’ represent the quantities available for
sale in the pharmacies. Correction for unused tablets due to
expiry is not possible since no valid data are available.
Figures from 1986 onwards were available for the fol-
lowing countries: Germany, Switzerland, Austria, Belgium,
Canada, Australia, France, Sweden, and the USA. No fig-
ures were available from the USA for 1995. Except for the
first reading point in 1986, the analysis was performed in
5-year intervals.
We began by comparing the different countries that
were compared over the period from 1986 to 2005 and
followed this with an exemplary analysis of the situation in
Germany since 1980 by comparing Germany (West) with
Germany (all) and prescription with non-prescription
analgesics. Long-term trends could only be shown for the
former western part of Germany as no long-term data are
available for the former eastern part.
Only analgesics of ATC code (Anatomical Therapeutic
Chemical Classification System as provided by the WHO)
N2B (general analgesics) were included; narcotics (N2A),
migraine remedies (N2C), and spasmolytics (A3D) were not
considered for this analysis. N2B analgesics include both
prescription and non-prescription analgesics. Their compo-
sitions were identified by using international drug
directories (e.g. Rote Liste for Germany, Physician’s Desk
Reference for the USA). In Germany, the substances of non-
prescription N2B analgesics include acetylsalicylic acid
(ASA), paracetamol or ibuprofen, either as single agents or
in combination. The N2B prescription drugs in Germany
include substances such as metamizole, tilidine plus nalox-
one, codeine, or tramadol as single agents or in combination.
Sales figures were converted into standardised units
(SU) in order to control for the different package sizes and
formulations (see Appendix 1). The conversion formulas
varied depending on the different formulations. For many
products one tablet equaled 1 SU. Per-capita consumption
was calculated by dividing the defined SU by the official
population figures in the respective countries and years
(data obtained from Statistisches Bundesamt, Wiesbaden,
Germany).
For further analysis the following categories were created
according to the number of agents: (A1) single analgesics
(contain 1 agent); (A2) combination analgesics (contain
two agents at least, e.g. paracetamol, acetylsalicylic acid,
codeine, caffeine, or phenacetin). In another analysis, cate-
gory A2 was subdivided into: (A21) caffeine-containing
multiple combination analgesics with two analgesic agents
at least plus caffeine, and (A22) other combination anal-
gesics. Low-dose ASA products (B300 mg for platelet
aggregation inhibition/prevention of vascular events) were
not counted among the analgesics and remained unconsi-
dered. Preparations containing vitamins and one analgesic
substance were classified as single analgesics. Products with




The international comparison for 2005 shows that the
highest per-capita consumption among the countries
included was observed in Sweden (147 SU per inhabitant,
Fig. 1), followed by France with 141 SU, Australia with
106, Canada with 81, Belgium with 66, and the USA with
61 SU. Germany (All) with 51 SU, Switzerland with 46,
and Austria with 42 SU showed the lowest per-capita
consumption in international comparison. Per-capita con-
sumption in Austria, Switzerland and Germany is only one-
third to one half that in other countries. The development
from 1986 to 2005 reveals two groups: One group with
Germany, Austria, Switzerland and Belgium, whose per-
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and remained constant or showing a minor increase only
(Switzerland, Belgium) during this period (Fig. 2). In the
other group, comprising Canada, Australia, France, and
Sweden, per-capita consumption in 1986 was distinctly
higher than in the first group, ranging between 57 SU (Aus)
to 105 SU (S).
The up to threefold higher consumption in Sweden and
France cannot be explained by use of products with basically
different compositions, e.g. ASA products. Comparisons
between an unweighted presentation and a presentation
weighted with mg ASA reveals no significant differences in
the distribution of the SU values of ASA single products
(Table 1). The weighting takes into account the different
ASA doses per SU by multiplying the respective consump-
tion figures (SU figures) per product by the corresponding
weighting factor (equivalent ASA dose in mg) and dividing












USA Canada Belgium Australia France Sweden
All analgesics
Single analgesics
Standardised medication units (SU) per capitaFig. 2 Trend of analgesic
consumption comparing all
analgesics with single
analgesics in the years 1986,
1990, 1995, 2000, 2005 (data
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All analgesics
Caffeine containing combinations




combinations in the years 1986,
1990, 1995, 2000, 2005 (data
for 1995 in USA not available)
Table 1 Relative proportions of standardised medication units (SU)

















Total 9 Countries 100 100
100% = overall consumption of acetylic salicylic acid (ASA) among
9 countries
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It stands out that in countries with high analgesic use,
such as Sweden and France, consumption increased again
considerably between 1986 and 2005 to 141 (F) and 147
(S) (Fig. 2). In both absolute figures and percentages, this
increase is clearly higher than in the first group. In the first
group annual consumption increased in Germany (West)
from 45 to 52 SU (+16%) and in Switzerland from 35
to 46 SU (+31%). In the second group, in contrast,
consumption increased in Australia from 57 to 106 SU
(+86%), in France from 74 to 141 (+91%), and in Sweden
from 105 to 147 SU (+40%).
The high per-capita consumption in Sweden and France is
based on a high increase in single products in the past 15 to
20 years (Fig. 2); this is also true of Australia (third highest
analgesic use). In Germany and Switzerland the use of single
analgesics has also increased over the past 20 years—
associated with a (minor) increase in overall analgesic
consumption over the last 5 years. In the past a short-term
increase in single analgesics in Austria caused a higher
overall consumption in 1995, which subsided thereafter,
accompanied by a decrease in single analgesics. Today
Austria has the lowest rate of single products in international
comparison and the lowest total consumption of all countries
studied. In the USA a reduction in the use of single products
is accompanied by a decrease in overall consumption.
Caffeine-containing multiple combinations (at least two
analgesic agents plus caffeine) are of minor relevance in
international comparison and do not explain the increasing
overall use in some countries (Fig. 3).
The correlation analysis across different countries and
time points confirms the association between the use of
single analgesics and overall analgesic use (Fig. 4). We
y = 1.1614x + 13.114





























Fig. 4 Ecological analysis
between consumption of all
analgesics with single
analgesics in the years 1986,
1990, 1995, 2000, 2005
considering the countries
Switzerland, Germany (West),
France, USA, Canada, Belgium,
Austria, Sweden and und
Australia (data for 1995 in USA
not available)
y = -2.1491x + 84.125





























Fig. 5 Ecological analysis
between consumption of all
analgesics with caffeine-
containing multiple analgesic
combinations in the years 1986,
1990, 1995, 2000, 2005
considering the countries
Switzerland, Germany (West),
France, USA, Canada, Belgium,
Austria, Sweden and und
Australia (data for 1995 in USA
not available)
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showed that a strong relationship (r2 = 81.8%) exists
between the consumption of single analgesics and total
analgesic consumption.
In contrast, only a very weak correlation—and a negative
one—can be observed between caffeine-containing mul-
tiple combinations and overall consumption (r2 = 19.7%;
Fig. 5). This supports the statement that this product group of
multiple combinations does not contribute to the increased
use on a population level, but rather even counteracts higher
overall consumption.
Analysis Germany
Per-capita consumption of analgesics in Germany (West)
has been very stable over the past 25 years and, at 52 SU
per capita per year, is currently slightly higher than the
long-term average (increase since 2000: approx. +1 SU
p.a.). There is no difference between Germany (West) and
Germany (all) (Fig. 6).
Most of the analgesics of the N2B market considered
here (market for general analgesics) can be bought without
prescription over the counter in pharmacies (Fig. 7).
Between 1986 and 1995 the consumption of prescription-
free analgesics increased markedly from 25.0 to 42.7 SU
per capita per year and in 1995 comprised approx. 88% of
all analgesics used, while the percentage of prescription
analgesics decreased by approx. 71%. This picture has
been changing since 1995 with prescription analgesics
tripling to approx. 18 SU per capita per year, while the
OTC analgesics decreased by approx. 19%. The increase in
prescription drug consumption since 1995 is primarily
responsible for the slight increase in overall analgesics and
is now back at the level of 1986. No consumption of any
phenacetin-containing analgesics has been observed in
Germany since 1986.
In 2005 in the prescription (Rx) group of N2B analge-
sics, combination products accounted for approx. 42% of


















Standardised medication units (SU) per capita
Germany (all)
Fig. 6 Trend of analgesic
consumption in Germany
(West) from 1980 until 2005;
Comparison between Germany
















1986 1990 1995 2000 2005
OTC
RX
Standardised medication units (SU) per capitaFig. 7 Trend of analgesic
consumption in Germany
(West) from 1980 until 2005
comparing prescription-free
(OTC) with prescription (Rx)
analgesics
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combinations are codeine plus paracetamol (18% of all SU
in the Rx group), followed by tilidine plus naloxone (12%).
The predominating single products in the Rx group are
metamizole (28%) and tramadol (23%). Growth in the Rx
group can be seen for both the combinations named and the
single products.
Discussion
This is the first investigation providing reliable, interna-
tionally comparable analyses of analgesic use in nine
countries over a period of 20 years. The data from the
database of the Institute of Medical Statistics provide a
sound and valid basis. The ‘‘consumption data’’ collected
represent the supplies available for sale in the pharmacies.
Because of the nature of per-capita consumption data it is
theoretically possible that the amounts of unused (expired)
medications might be different in the various countries.
However, no data on this are available. Even if we assume
that such differences exist, it is hardly conceivable that the
differences in unused medication between countries would
be high enough to explain the considerable differences in
per-capita consumption alone.
On international comparison, Austria, Switzerland and
Germany show the lowest per-capita consumption of anal-
gesics. In Sweden and France consumption is three times as
high, which is attributed to the high increase in single
products over the past 15–20 years. It is difficult to assess to
what extent these differences can be explained by different
prevalences of painful disorders, such as shown for head-
ache disorders at least for various world regions [2], since
the required country-specific data are not available.
Recently, consumption of single analgesics has
increased slightly in Germany and Switzerland. Austria
today has the lowest proportion of single products in
international comparison. In the USA a decrease in the use
of single products is accompanied by a decrease in overall
analgesic consumption. The correlation analysis over the
different countries and time points confirms the positive
correlation between use of single analgesics and overall
analgesics consumption. Caffeine-containing multiple
combinations containing two analgesic agents plus caffeine
are of minor relevance in international comparison and thus
cannot be causally related to the sharply rising overall
consumption in some countries. The correlation analysis
also shows that this product group does not contribute to
the high analgesic consumption on a population level—on
the contrary it rather counteracts this phenomenon.
In Germany per-capita consumption of analgesics has
remained nearly unchanged at approx. 50 SU per capita per
year since 1980. It is currently 52 SU per capita per year and
thus slightly higher than the long-term average. There is no
difference between Germany (West) and Germany (all).
These consumption figures, which are very stable in inter-
national comparison, were already seen from 1970 to 1986
[1]. They varied between 47 and 54 SU per capita per year,
with a continuous decrease after 1979, the year with the
highest consumption. Two-thirds of the current per-capita
consumption in Germany comprises OTC analgesics. The
increase in the use of prescription drugs since 1995 has led to
a slight increase in overall consumption, which is now back
at the level of 1986. This could be explained by an increasing
number (possibly age-related) pain patients or a certain
previous undersupply with analgesics of the latter. Phenac-
etin-containing analgesics, which in the 1970s still held a
market share of up to 40%, were taken from the market in
1986. Caffeine-containing analgesics have shown a contin-
uous decrease (by approx. 1 SU per year) since 1980.
For all OTC analgesics (except the 400 mg ibuprofen
products) the recommended dose is one to two tablets three
times daily. The epidemiological headache study con-
ducted by the German Migraine and Headache Society
between 2003 and 2005 (first results were presented at the
German Pain Congress 2006) showed that the headache
prevalence over 1 year is approx. 60% and that about one-
third of the German adult population suffer from headaches
more than once per month. If we assume that these patients
suffer from their migraine or headaches for 2–3 days per
month and that they treat their condition with half the
recommended maximum daily dose, i.e. 3 9 1 tablet per
day, we receive a calculated per-capita consumption of
40 SU per year for the total population (estimated 45%
affected). The appropriate use of analgesics for the self-
treatment of these indications alone can explain the per-
capita consumption of approx. 40 SU per year. Some of the
affected people will undoubtedly successfully treat their
headaches without medication or with an even lower daily
dose. In addition to headache treatment, there is the treat-
ment of pain of other etiologies (e.g. toothache,
menstruation-induced pain, cold-induced pain, low back
pain) and almost all analgesic use prescribed by doctors.
Consequently the consumption figures in Germany and
other countries do not support the claim of an inappropri-
ately high use of analgesics on a population level. The
prevalence of the conditions in which analgesic use is
indicated, as the most relevant criterion for analgesic
consumption, is frequently underestimated. Although we
definitely do not wish to trivialise the risks of analgesic
abuse in general, or of medication overuse headache in
particular, it is important to realise that estimates from
analgesic consumption studies on population level as this
are not adequate to provide scientifically founded data on
analgesic consumption by specific patient groups.
In conclusion, it has been shown that great differences
exist in the per-capita consumption of analgesics between
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different countries. These differences seem to be due to the
impact of single analgesics: countries with increasing
amounts of single analgesics likewise show an increase in
their total supplies of analgesics. In countries such as Aus-
tria, where consumption with single analgesics is decreasing,
the total consumption of analgesics also decreases and
actually shows the lowest per-capita consumption among the
considered countries. On the other hand, there is no corre-
lation between the consumption of caffeine-containing
analgesics and total analgesic consumption. Per-capita use
of analgesics in Germany has been relatively stable at
approx. 50 SU per capita per year over the past 25 years.
There is no difference between Germany (West) and Ger-
many (all). Taking into account the prevalence of the
conditions prompting analgesics consumption, we can con-
clude appropriate use of analgesics on total population level.
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Table 2 Example for an SU calculation
Country A (a) (b) (c) (d)














ASA 800 20 16,000
600 30 18,000
Paracetamol 1,000 10 10,000
400 30 12,000
500 250 12,500
Total 68,500 1,500 46
Year 2005
ASA 700 20 14,000
900 30 27,000
Paracetamol 800 10 8,000
350 30 10,500
450 200 9,000
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